Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest
Parker Institute gathers its investigators’ cell therapy technologies into cancer cell therapy newco ArsenalBio
ArsenalBio launched Thursday with $85 million in a series A round to combine the technologies of its six Parker Institute co-founders into a suite of tools the company thinks could overcome key hurdles to cell therapy for solid tumors.
Arsenal Biosciences Inc. is among the first disclosed companies to originate from the Parker Institute for Cancer Immunotherapy (PICI) as an extension of its aim to bring investigators and technologies from different academic research centers under one roof.
The institute has invested in and partnered with